News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
633,737 Results
Type
Article (48605)
Company Profile (219)
Press Release (584912)
Multimedia
Podcasts (131)
Webinars (20)
Section
Business (177558)
Career Advice (2595)
Deals (32700)
Drug Delivery (125)
Drug Development (79257)
Employer Resources (165)
FDA (16446)
Job Trends (13702)
News (314636)
Policy (32646)
Tag
Academia (2431)
Academic (1)
Accelerated approval (14)
Adcomms (33)
Allergies (99)
Alliances (45031)
ALS (118)
Alzheimer's disease (1568)
Antibody-drug conjugate (ADC) (183)
Approvals (16401)
Artificial intelligence (344)
Autoimmune disease (37)
Automation (16)
Bankruptcy (330)
Best Places to Work (10193)
BIOSECURE Act (22)
Biosimilars (138)
Biotechnology (112)
Bladder cancer (99)
Brain cancer (37)
Breast cancer (378)
Cancer (2969)
Cardiovascular disease (238)
Career advice (2167)
Career pathing (34)
CAR-T (188)
CDC (43)
Cell therapy (527)
Cervical cancer (23)
Clinical research (65476)
Collaboration (1033)
Company closure (3)
Compensation (724)
Complete response letters (38)
COVID-19 (2717)
CRISPR (61)
C-suite (354)
Cystic fibrosis (114)
Data (3073)
Decentralized trials (2)
Denatured (35)
Depression (80)
Diabetes (352)
Diagnostics (5724)
Digital health (22)
Diversity (9)
Diversity, equity & inclusion (43)
Drug discovery (152)
Drug pricing (153)
Drug shortages (35)
Duchenne muscular dystrophy (156)
Earnings (71663)
Editorial (50)
Employer branding (20)
Employer resources (148)
Events (96794)
Executive appointments (849)
FDA (18250)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (887)
Gene editing (133)
Generative AI (29)
Gene therapy (421)
GLP-1 (914)
Government (4193)
Grass and pollen (7)
Guidances (214)
Healthcare (16067)
HIV (43)
Huntington's disease (32)
IgA nephropathy (44)
Immunology and inflammation (187)
Immuno-oncology (13)
Indications (41)
Infectious disease (2909)
Inflammatory bowel disease (155)
Inflation Reduction Act (11)
Influenza (70)
Intellectual property (123)
Interviews (476)
IPO (15457)
IRA (55)
Job creations (3871)
Job search strategy (1810)
Kidney cancer (14)
Labor market (53)
Layoffs (571)
Leadership (27)
Legal (7912)
Liver cancer (81)
Longevity (12)
Lung cancer (419)
Lymphoma (215)
Machine learning (12)
Management (58)
Manufacturing (442)
MASH (101)
Medical device (11694)
Medtech (11699)
Mergers & acquisitions (17977)
Metabolic disorders (938)
Multiple sclerosis (106)
NASH (23)
Neurodegenerative disease (148)
Neuropsychiatric disorders (46)
Neuroscience (2321)
NextGen: Class of 2025 (5537)
Non-profit (3445)
Now hiring (40)
Obesity (492)
Opinion (277)
Ovarian cancer (96)
Pain (121)
Pancreatic cancer (125)
Parkinson's disease (197)
Partnered (19)
Patents (323)
Patient recruitment (173)
Peanut (50)
People (52975)
Pharmaceutical (89)
Pharmacy benefit managers (25)
Phase I (20173)
Phase II (28451)
Phase III (22157)
Pipeline (1741)
Policy (250)
Postmarket research (2611)
Preclinical (8250)
Press Release (50)
Prostate cancer (151)
Psychedelics (45)
Radiopharmaceuticals (253)
Rare diseases (520)
Real estate (5417)
Recruiting (66)
Regulatory (23338)
Reports (39)
Research institute (2238)
Resumes & cover letters (427)
Rett syndrome (9)
RNA editing (10)
RSV (57)
Schizophrenia (104)
Series A (159)
Series B (106)
Service/supplier (14)
Sickle cell disease (67)
Special edition (22)
Spinal muscular atrophy (156)
Sponsored (36)
Startups (3351)
State (2)
Stomach cancer (17)
Supply chain (83)
Tariffs (71)
The Weekly (94)
Vaccines (903)
Venture capital (59)
Weight loss (333)
Women's health (43)
Worklife (20)
Date
Today (21)
Last 7 days (516)
Last 30 days (1729)
Last 365 days (30522)
2025 (17924)
2024 (33902)
2023 (37955)
2022 (48576)
2021 (52355)
2020 (49729)
2019 (40557)
2018 (30959)
2017 (31273)
2016 (30064)
2015 (33726)
2014 (27398)
2013 (23039)
2012 (24702)
2011 (25296)
2010 (23250)
Location
Africa (792)
Alabama (56)
Alaska (7)
Arizona (201)
Arkansas (12)
Asia (39425)
Australia (6339)
California (7357)
Canada (2161)
China (671)
Colorado (312)
Connecticut (339)
Delaware (205)
Europe (89223)
Florida (1135)
Georgia (232)
Hawaii (3)
Idaho (46)
Illinois (607)
India (30)
Indiana (324)
Iowa (18)
Japan (238)
Kansas (96)
Kentucky (28)
Louisiana (13)
Maine (67)
Maryland (1039)
Massachusetts (5602)
Michigan (213)
Minnesota (427)
Mississippi (3)
Missouri (83)
Montana (18)
Nebraska (22)
Nevada (78)
New Hampshire (58)
New Jersey (2093)
New Mexico (26)
New York (2025)
North Carolina (1100)
North Dakota (7)
Northern California (3289)
Ohio (208)
Oklahoma (11)
Oregon (32)
Pennsylvania (1554)
Puerto Rico (15)
Rhode Island (29)
South America (1165)
South Carolina (33)
South Dakota (1)
Southern California (2776)
Tennessee (117)
Texas (1077)
United States (27173)
Utah (189)
Virginia (194)
Washington D.C. (74)
Washington State (621)
West Virginia (4)
Wisconsin (72)
633,737 Results for "ascendis pharma a s".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025
July 31, 2025
·
3 min read
Press Releases
Ascendis Pharma Reports First Quarter 2025 Financial Results
May 1, 2025
·
11 min read
Press Releases
Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025
April 25, 2025
·
3 min read
Press Releases
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ENDO 2025
July 8, 2025
·
6 min read
Press Releases
Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference
February 24, 2025
·
3 min read
Press Releases
Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results
February 12, 2025
·
14 min read
Business
Ascendis Pharma Reports First Quarter 2024 Financial Results
Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the first quarter ended March 31, 2024, and provided a business update.
May 2, 2024
·
12 min read
Press Releases
FDA Accepts Ascendis Pharma’s Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency
December 12, 2024
·
5 min read
Press Releases
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets
January 13, 2025
·
3 min read
Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with Hypoparathyroidism
Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food and Drug Administration (FDA) notified the Company that information submitted in response to the FDA’s ongoing review of the New Drug Application (NDA) for TransCon PTH (palopegteriparatide) for adults with hypoparathyroidism constituted a major amendment to the NDA.
May 14, 2024
·
4 min read
1 of 63,374
Next
